Google plans to publish new “open” AI models for the discovery of drugs
During an event focused on New York on Tuesday, Google announced that it was developing a collection of “open” AI models for the discovery of drugs called TXGEMMA.
AI models, which, according to Google, will be published via its Foundations of health AI developers Program later this month, can include both the “regular text” and the structures of different “therapeutic entities”, including chemicals, molecules and proteins, depending on the company.
“The development of therapeutic drugs from the concept to approved use is a long and expensive process, so we work with the wider research community to find new ways to make this development more effective,” wrote Karen Desalvo, head of health of Google, in a blog article provided to Techcrunch. “”[R]Researchers can ask TXGEMMA questions to help predict the important properties of potential new therapies, such as the safety or efficiency they may be. »»
Google has not said if the model license will allow commercial use, personalization or fine adjustment. Techcrunch contacted the company for more information and was up to date if the company reacts.
Countless companies, including the Google spin-out ISOMorphic Laboratorieshave promised that AI could one day revolutionize the discovery of drugs by considerably accelerating the first stages of R&D. Although there were successes, AI has not provided an immediate magic solution in the laboratory.
Several companies employing an AI for the discovery of drugs, including Excivia and Beenvensuffered high -level Failure of clinical trials in recent years. Meanwhile, the accuracy of the main AI systems for the discovery of drugs, such as Google Deepmind Alphafold 3,, tends to vary considerably.
However, Big Pharma – and investors – seem enthusiastic about the potential of technology. In January, Isomorphic, who has partnerships with pharmaceutical giants Eli Lilly and Novartis, said he expects tests on his drugs designed by AI is starting this year. By one estimateOver 460 AI startups work on the discovery of drugs, and Investors have paid $ 60 billion in space so far.
